Featured Articles

UCB and Ra Pharmaceuticals Inc. announced their entry into a merger agreement pursuant for which UCB will acquire Ra Pharma. Under the terms of the agreement, Ra Pharma shareholders…
Read More...

GlaxoSmithKline announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab) for use in children as young as six years old who are living with severe…
Read More...

Mallinckrodt plc, a global biopharmaceutical company, today announced it has entered into a definitive agreement to sell its wholly owned subsidiary BioVectra Inc. to an affiliate of…
Read More...

Boehringer Ingelheim and Lupin Limited (Lupin) announced a licensing, development and commercialization agreement for Lupin’s MEK inhibitor compound (LNP3794) as a potential targeted…
Read More...

AstraZeneca announced that its partner FibroGen (China) Medical Technology Development Co., Ltd. (FibroGen China) has received marketing authorisation for roxadustat in China for the…
Read More...

AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) announced positive results from the Phase III PAOLA-1 trial in women with…
Read More...

Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center announced a new multi-year partnership to conduct collaborative research to rapidly advance therapies for…
Read More...

Bayer AG and BlueRock Therapeutics announced an agreement under which Bayer will fully acquire BlueRock Therapeutics, a privately held US-headquartered biotechnology company focused on…
Read More...

Takeda Pharmaceutical Company Limited announced that it has submitted a New Drug Application (NDA) to the Ministry of Health, Labour and Welfare in Japan for a subcutaneous (SC)…
Read More...

Samsung BioLogics (SBL) and UCB have agreed to an additional drug substance manufacturing deal under which SBL will also produce UCB's anti-tau candidate to treat progressive…
Read More...

Pfizer Inc. announced the closing of its joint venture with GlaxoSmithKline plc to combine the parties’ respective consumer healthcare businesses to create the world’s largest…
Read More...

Novartis announced Kisqali (ribociclib) achieved statistically significant improvement in overall survival in the Phase III MONALEESA-3 clinical trial. This is the second Phase III…
Read More...

Baxter International Inc. announced the U.S. Food and Drug Administration (FDA) approval of Myxredlin (Insulin Human in 0.9% Sodium Chloride Injection). Myxredlin (pronounced…
Read More...

Sandoz, a Novartis division and a global leader in biosimilars, announced the first patient enrolled in ROSALIA, an integrated Phase I/III clinical study for its proposed biosimilar…
Read More...

Celltrion and Nan Fung Group announced the establishment of Vcell Healthcare Limited, a Joint Venture company between both parties. At the formation of the Joint Venture, Vcell…
Read More...

MilliporeSigma and the Broad Institute of MIT and Harvard announced an agreement to offer non-exclusive licenses to CRISPR intellectual property (IP) under their respective control for…
Read More...

The U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for isatuximab for the treatment of patients with relapsed/refractory…
Read More...

AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada)  announced that Lynparza (olaparib) has been approved in Japan as a…
Read More...

Gilead Sciences, Inc. and Nurix Therapeutics, Inc., a company discovering drugs that harness the body’s natural process to control protein levels, today announced a global strategic…
Read More...

Pfizer Inc. and Array BioPharma Inc. announced that they have entered into a definitive merger agreement under which Pfizer will acquire Array, a commercial stage biopharmaceutical…
Read More...